NasdaqGS:REGNBiotechs
Regeneron Pharmaceuticals (REGN): Evaluating Valuation Following Breakthrough Phase 3 Allergy Drug Results
If you’re wondering whether now is the time to take a closer look at Regeneron Pharmaceuticals (REGN), you’re not alone. The company’s recent announcement of promising Phase 3 results for its innovative allergen-blocking antibodies, which target moderate to severe cat or birch allergies, has caught the attention of investors. This meaningful step forward in their allergy pipeline points to the potential for new regulatory submissions and a deeper foothold in a space with unmet patient...